The acquisition of Avivia aligns with Ofichem’s broader merger and acquisition agenda and ongoing investment strategy.

Replacing defective microglia can halt ALSP—a fatal neurodegenerative disease—in mice and humans, offering hope for broader brain therapies.

A newly developed generative AI model is helping researchers explore protein dynamics with increased speed. The deep learning system, called BioEmu, predicts the full range of conformations a protein ...

The designed proteins block hemoglobin from binding ChuA, an outer membrane bacterial protein, helping to inhibit E. coli's growth.

Pharmaceutical manufacturers are under immense pressure to streamline their processes, reduce waste, and improve output.

Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...

GREmLN leverages a graph-based architecture to represent gene-gene interactions to predict cell behavior for therapeutic ...

Methylation changes in microbiome-derived cfRNA enable more accurate CRC diagnosis than traditional DNA or abundance-based ...

Mouse livers were engineered via a one-time genome editing to secrete a GLP-1, cutting weight gain and improving glucose ...

Revolution Medicines' proprietary data will train a bespoke version of NeuralPLexer, an AI model for protein-ligand ...

Fujifilm’s Life Sciences Group is renaming two of its companies, in a rebranding intended to position parent company Fujifilm ...

Results reveal that weight loss has significant effects on cellular processes that are known to affect metabolic health and ...